JP2023520469A5 - - Google Patents
Info
- Publication number
- JP2023520469A5 JP2023520469A5 JP2022559934A JP2022559934A JP2023520469A5 JP 2023520469 A5 JP2023520469 A5 JP 2023520469A5 JP 2022559934 A JP2022559934 A JP 2022559934A JP 2022559934 A JP2022559934 A JP 2022559934A JP 2023520469 A5 JP2023520469 A5 JP 2023520469A5
- Authority
- JP
- Japan
- Prior art keywords
- fenebrutinib
- pharmaceutically acceptable
- acceptable salt
- subject
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063005095P | 2020-04-03 | 2020-04-03 | |
| US63/005,095 | 2020-04-03 | ||
| US202063051767P | 2020-07-14 | 2020-07-14 | |
| US63/051,767 | 2020-07-14 | ||
| PCT/US2021/025301 WO2021202825A1 (en) | 2020-04-03 | 2021-04-01 | Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026071127A Division JP2026133417A (ja) | 2020-04-03 | 2026-04-22 | ブルトン型チロシンキナーゼの阻害剤を使用する再発性多発性硬化症の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023520469A JP2023520469A (ja) | 2023-05-17 |
| JP2023520469A5 true JP2023520469A5 (cg-RX-API-DMAC7.html) | 2024-04-10 |
Family
ID=75625678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022559934A Pending JP2023520469A (ja) | 2020-04-03 | 2021-04-01 | ブルトン型チロシンキナーゼの阻害剤を使用する再発性多発性硬化症の治療方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12605376B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4125906A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023520469A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220163986A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115916205A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021249129B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022019846A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3177390A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2022002699A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL296990A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022012310A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI907406B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021202825A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI899163B (zh) * | 2020-02-28 | 2025-10-01 | 美商建南德克公司 | 使用布魯頓氏酪胺酸激酶之抑制劑來治療首發漸進型多發性硬化症之方法 |
| BR112023021235A2 (pt) | 2021-05-14 | 2023-12-12 | Loxo Oncology Inc | Formas cocristalinas de um inibidor da tirosina quinase de bruton |
| CN114028393B (zh) * | 2021-11-07 | 2023-07-18 | 天津医科大学 | 阿帕替尼在制备治疗多发性硬化症药物的用途 |
| WO2024238524A1 (en) * | 2023-05-16 | 2024-11-21 | Genentech, Inc. | Methods of treating relapsing multiple sclerosis using an inhibitor of bruton's tyrosine kinase |
| WO2025264860A2 (en) | 2024-06-18 | 2025-12-26 | Yale University | Methods of treating post-covid airway disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| US9545407B2 (en) | 2014-08-07 | 2017-01-17 | Pharmacyclics Llc | Formulations of a bruton's tyrosine kinase inhibitor |
| PL4049660T3 (pl) | 2016-02-29 | 2025-06-09 | F. Hoffmann-La Roche Ag | Kompozycje postaci dawkowania zawierające inhibitor kinazy tyrozynowej Brutona |
| CN107043366B (zh) | 2017-04-25 | 2020-05-26 | 中国药科大学 | 4-氨基嘧啶类化合物、其制备方法及医药用途 |
| EP3626239B1 (en) | 2017-05-18 | 2024-07-03 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Ezh2 inhibitor combined with btk inhibitor for treating tumor |
| US20210113568A1 (en) * | 2018-04-27 | 2021-04-22 | Ono Pharmaceutical Co., Ltd. | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT |
| JP2022500408A (ja) * | 2018-09-12 | 2022-01-04 | デノボ バイオファーマ エルエルシー | エンザスタウリンとbtkの阻害剤との組合せおよびその使用 |
| EP3914250A1 (en) | 2019-01-22 | 2021-12-01 | F. Hoffmann-La Roche AG | Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase |
| TWI899163B (zh) | 2020-02-28 | 2025-10-01 | 美商建南德克公司 | 使用布魯頓氏酪胺酸激酶之抑制劑來治療首發漸進型多發性硬化症之方法 |
-
2021
- 2021-04-01 TW TW110112266A patent/TWI907406B/zh active
- 2021-04-01 IL IL296990A patent/IL296990A/en unknown
- 2021-04-01 BR BR112022019846A patent/BR112022019846A2/pt unknown
- 2021-04-01 CA CA3177390A patent/CA3177390A1/en active Pending
- 2021-04-01 WO PCT/US2021/025301 patent/WO2021202825A1/en not_active Ceased
- 2021-04-01 EP EP21720649.9A patent/EP4125906A1/en active Pending
- 2021-04-01 JP JP2022559934A patent/JP2023520469A/ja active Pending
- 2021-04-01 US US17/995,259 patent/US12605376B2/en active Active
- 2021-04-01 KR KR1020227037384A patent/KR20220163986A/ko active Pending
- 2021-04-01 AU AU2021249129A patent/AU2021249129B2/en active Active
- 2021-04-01 MX MX2022012310A patent/MX2022012310A/es unknown
- 2021-04-01 CN CN202180035499.8A patent/CN115916205A/zh active Pending
-
2022
- 2022-09-30 CL CL2022002699A patent/CL2022002699A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7807870B2 (ja) | うつ病の治療のためのエスケタミン | |
| US20220152056A1 (en) | Methods and compositions for treating various disorders | |
| JP6014655B2 (ja) | うつ病および不安を予防し治療するためのタペンタドール | |
| US12090148B2 (en) | Treatment of migraine | |
| EP3206682B1 (en) | Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis | |
| CN105311029A (zh) | 抗肿瘤活性的喹啉衍生物 | |
| WO2022177718A1 (en) | Use of neuroactive steroid for treatment of sexual dysfunction | |
| JP2018502898A (ja) | 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および/または代謝疾患の処置のための、脳由来神経栄養因子(bdnf)の誘導された発現 | |
| AU2021205465A1 (en) | Methods of treating conditions related to the S1P1 receptor | |
| TW201204360A (en) | Treatment of multiple sclerosis with MASITINIB | |
| US20220395472A1 (en) | Remittive effects of tapinarof in the treatment of plaque psoriasis, atopic dermatitis, or radiation dermatitis | |
| JP2022532098A5 (cg-RX-API-DMAC7.html) | ||
| JP2025513240A5 (cg-RX-API-DMAC7.html) | ||
| Frackiewicz et al. | Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa | |
| JP2021530568A5 (cg-RX-API-DMAC7.html) | ||
| KR20100002304A (ko) | 안진 치료용 네라멕산 | |
| JP7219476B2 (ja) | 腱滑膜病変を主体とした疾患の治療薬 | |
| US20200038414A1 (en) | Methods of treating constipation using aminosterol compositions | |
| RU2022127814A (ru) | Способы лечения рецидивирующего рассеянного склероза с применением ингибитора тирозинкиназы брутона | |
| CA3100635A1 (en) | Combinations comprising tropifexor and cenicriviroc | |
| JP2022546042A5 (cg-RX-API-DMAC7.html) | ||
| TW201932114A (zh) | 化合物用於炎症介導的視神經病變的治療 | |
| KR20250160957A (ko) | 척수성 근위축증의 치료를 위한 조성물 및 방법 | |
| WO2025018279A1 (ja) | ヒト移植片対宿主病の治療薬およびその組合せ物 | |
| WO2025096942A1 (en) | Trimeprazine for use in treating pain associated with trigeminal neuralgia |